|
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent. The primary objective is to demonstrate the equivalence of three batches of DTaP-IPV-HB-PRP~T vaccine, in terms of seroprotection and seroconversion rates for the vaccine antigens after the three-dose primary series. The secondary objectives are:
U.S. FDA Resources
Further study details as provided by Sanofi-Aventis: Primary Outcome Measures:
Eligibility
Criteria Inclusion Criteria :
Exclusion Criteria :
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00404651 Locations
Sponsors and Collaborators
Investigators
More Information
Keywords provided by Sanofi-Aventis:
Study placed in the following topic categories:
Additional relevant MeSH terms:
Source: National Library of Medicine (NLM) June 26, 2008 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Browse All News Categories
Business
|
Consumer
|
Education
|
Entertaiment
|
Family & Community
|
Health
|
Law
|
Offbeat
|
Politics
|
Science
|
Sports
|
Technology
|
Weather
|
World News
|
||
|
News Archive
|
||


